RxDoctor Payments Data

Mitchell Mayer, DO

Family Medicine · Iselin, NJNPI 1639173008

Payments from drug & device makers

$7,646in general payments, 2019–2025

Across 517 payments — averaging $14.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$953
  • Pfizer$852
  • Novo Nordisk$826
  • Lilly USA, LLC$659
  • Bayer$579
  • Exact Sciences$486
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$7,646100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,646 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$111,536
Medicare patients
501
Services billed
1,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide153$224,953
JardianceEmpagliflozin132$165,744
MounjaroTirzepatide98$128,073
EliquisApixaban97$90,337
FarxigaDapagliflozin Propanediol67$78,439
TrulicityDulaglutide47$74,147
JanuviaSitagliptin Phosphate35$44,900
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$40,713
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog49$33,533
XareltoRivaroxaban19$23,983
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr43$21,488
Tresiba Flextouch U-200Insulin Degludec24$17,652
RybelsusSemaglutide15$16,407
MyrbetriqMirabegron24$15,854
ShingrixVaricella-Zoster Ge/As01b/Pf62$13,659

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$826$241,360168 claims
Lilly USA, LLCMounjaro, Trulicity$659$202,220145 claims
Boehringer IngelheimJardiance$259$165,744132 claims
GSKTrelegy Ellipta, Anoro Ellipta, Shingrix, Breo Ellipta, Arexvy$407$91,852180 claims
PfizerEliquis$852$90,33797 claims
AstraZenecaFarxiga$953$78,43967 claims
MerckJanuvia$242$44,90035 claims
Johnson & JohnsonXarelto$146$23,98319 claims
Astellas Pharma US IncMyrbetriq$49$15,85424 claims
NovartisEntresto$124$8,87411 claims
AbbVieSynthroid$98$3,39456 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Iselin

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →